Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, uppe… Read more
Marksans Pharma Limited (MARKSANS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.028x
Based on the latest financial reports, Marksans Pharma Limited (MARKSANS) has a cash flow conversion efficiency ratio of 0.028x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹751.86 Million) by net assets (₹27.14 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Marksans Pharma Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Marksans Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Marksans Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marksans Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Calavo Growers Inc
NASDAQ:CVGW
|
0.011x |
|
AB Ignitis grupe
IL:IGN
|
0.012x |
|
Guangzhou Grandbuy Co Ltd
SHE:002187
|
0.021x |
|
OSAKA Titanium technologies Co.Ltd
F:S5M
|
N/A |
|
ANGELALIGN TECHNOLOGY INC
PINK:AGLFF
|
N/A |
|
Shanghai SK Petroleum & Chemical Equipment Corp Ltd
SHE:002278
|
-0.009x |
|
Mah Sing Group Bhd
KLSE:8583
|
0.022x |
|
Cognyte Software Ltd
NASDAQ:CGNT
|
0.110x |
Annual Cash Flow Conversion Efficiency for Marksans Pharma Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Marksans Pharma Limited from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹24.89 Billion | ₹2.07 Billion | 0.083x | -24.84% |
| 2024-03-31 | ₹20.86 Billion | ₹2.30 Billion | 0.110x | -17.88% |
| 2023-03-31 | ₹17.65 Billion | ₹2.37 Billion | 0.135x | +65.73% |
| 2022-03-31 | ₹12.23 Billion | ₹992.57 Million | 0.081x | -58.89% |
| 2021-03-31 | ₹9.05 Billion | ₹1.79 Billion | 0.197x | -38.96% |
| 2020-03-31 | ₹6.49 Billion | ₹2.10 Billion | 0.323x | +552.52% |
| 2019-03-31 | ₹5.53 Billion | ₹273.95 Million | 0.050x | -59.59% |
| 2018-03-31 | ₹4.80 Billion | ₹589.20 Million | 0.123x | +525.30% |
| 2017-03-31 | ₹4.51 Billion | ₹88.42 Million | 0.020x | -70.54% |
| 2016-03-31 | ₹4.63 Billion | ₹308.00 Million | 0.067x | -83.29% |
| 2015-03-31 | ₹3.88 Billion | ₹1.55 Billion | 0.398x | -8.57% |
| 2014-03-31 | ₹1.49 Billion | ₹648.39 Million | 0.436x | +5.61% |
| 2013-03-31 | ₹934.69 Million | ₹385.60 Million | 0.413x | +7.58% |
| 2012-03-31 | ₹-1.62 Billion | ₹-622.96 Million | 0.383x | +160.26% |
| 2011-03-31 | ₹1.15 Billion | ₹-731.49 Million | -0.636x | -709.30% |
| 2010-03-31 | ₹1.62 Billion | ₹169.19 Million | 0.104x | -21.24% |
| 2009-03-31 | ₹1.51 Billion | ₹200.19 Million | 0.133x | -18.62% |
| 2008-03-31 | ₹1.42 Billion | ₹231.54 Million | 0.163x | +157.10% |
| 2007-03-31 | ₹1.26 Billion | ₹-360.59 Million | -0.285x | -- |